Research / WTW / Fundamental state Inspectable configuration
State dimensions Filing 0000950170-24-086379 Insurance
Cash 18th Own-history percentile · N=11
Evidence method Level · gp.fundamentals.cash
$1.2B · CORE · VALID
Debt 55th Own-history percentile · N=11
Evidence method Level · gp.fundamentals.gross_debt
$5.3B · OPTIONAL · VALID
Net-income growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.fundamentals.net_income
50.00% · CORE · NOT_ENOUGH_HISTORY
Revenue growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.fundamentals.revenue
4.77% · CORE · NOT_ENOUGH_HISTORY
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 14 states Self-history eligible
Sep 30, 2022 0/4 normalized Level 3 Dec 31, 2022 0/4 normalized Level 3 Mar 31, 2023 0/4 normalized Level 3 Jun 30, 2023 0/4 normalized Level 3 Sep 30, 2023 2/4 normalized Level 3 Dec 31, 2023 2/4 normalized Level 3 Mar 31, 2024 2/4 normalized Level 3 Jun 30, 2024 2/4 normalized Level 3 Sep 30, 2024 4/4 normalized Level 3 Dec 31, 2024 4/4 normalized Level 3 Mar 31, 2025 4/4 normalized Level 3 Jun 30, 2025 4/4 normalized Level 3 Mar 31, 2026 4/4 normalized Level 3 Jun 30, 2026 4/4 normalized Level 4 Period transition
What moved in the state? Cash Decreased
Previous $1.9B
Current $1.2B
Delta -$646.0M Debt Decreased
Previous $6.0B
Current $5.3B
Delta -$650.0M Earnings Growth Increased
Previous -6.40%
Current 50.00%
Delta 56.40% Revenue Growth Increased
Previous 4.18%
Current 4.77%
Delta 0.59% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.